Article
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Neoplasia (New York, N.Y.) - 1 Aug 2009
Ciuffreda Ludovica, Del Bufalo Donatella, Desideri Marianna, Di Sanza Cristina, Stoppacciaro Antonella, Ricciardi Maria Rosaria, Chiaretti Sabina, Tavolaro Simona, Benassi Barbara, Bellacosa Alfonso, Foà Robin, Tafuri Agostino, Cognetti Francesco, Anichini Andrea, Zupi Gabriella, Milella Michele
Abstract excerpt
The Raf/MEK/ERK pathway is an important mediator of tumor cell proliferation and angiogenesis. Here, we investigated the growth-inhibitory and antiangiogenic properties of PD0325901, a novel MEK inhibitor, in human melanoma cells. PD0325901 effects were determined in a panel of melanoma cell lines with different genetic aberrations. PD0325901 markedly inhibited ERK phosphorylation and growth of both BRAF mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.